BlackRock’s Anebulo Pharmaceuticals ANEB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-23,790
| Closed | -$24K | – | 5685 |
|
|
2025
Q4 | $24K | Sell |
23,790
-270
| -1% | -$616 | ﹤0.01% | 5184 |
|
|
2025
Q3 | $60.1K | Buy |
24,060
+6,847
| +40% | +$16.1K | ﹤0.01% | 4948 |
|
|
2025
Q2 | $24.8K | Buy |
17,213
+11,450
| +199% | +$13.1K | ﹤0.01% | 5109 |
|
|
2025
Q1 | $7.49K | Buy |
5,763
+1,834
| +47% | +$2.7K | ﹤0.01% | 5204 |
|
|
2024
Q4 | $6.6K | Buy |
3,929
+24
| +0.6% | +$40 | ﹤0.01% | 5204 |
|
|
2024
Q3 | $7.54K | Buy |
3,905
+144
| +4% | +$307 | ﹤0.01% | 5007 |
|
|
2024
Q2 | $10.3K | Sell |
3,761
-288
| -7% | -$731 | ﹤0.01% | 5069 |
|
|
2024
Q1 | $11.6K | Sell |
4,049
-96
| -2% | -$247 | ﹤0.01% | 5072 |
|
|
2023
Q4 | $10K | Sell |
4,145
-48
| -1% | -$113 | ﹤0.01% | 5146 |
|
|
2023
Q3 | $12.8K | Sell |
4,193
-3,060
| -42% | -$8.48K | ﹤0.01% | 5184 |
|
|
2023
Q2 | $17K | Sell |
7,253
-280
| -4% | -$699 | ﹤0.01% | 5217 |
|
|
2023
Q1 | $21.8K | Buy |
7,533
+240
| +3% | +$682 | ﹤0.01% | 5241 |
|
|
2022
Q4 | $17.7K | Buy |
7,293
+160
| +2% | +$421 | ﹤0.01% | 5390 |
|
|
2022
Q3 | $20K | Sell |
7,133
-200
| -3% | -$710 | ﹤0.01% | 5511 |
|
|
2022
Q2 | $38K | Sell |
7,333
-120
| -2% | -$502 | ﹤0.01% | 5467 |
|
|
2022
Q1 | $53K | Sell |
7,453
-360
| -5% | -$2.46K | ﹤0.01% | 5411 |
|
|
2021
Q4 | $49K | Buy |
7,813
+200
| +3% | +$1.33K | ﹤0.01% | 5402 |
|
|
2021
Q3 | $50K | Sell |
7,613
-160
| -2% | -$1.12K | ﹤0.01% | 5280 |
|
|
2021
Q2 | $53K | Buy |
+7,773
| New | +$57.8K | ﹤0.01% | 5175 |
|
BlackRock's ANEB Position: Q1 2026 in Review
BlackRock sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 23,790 shares — an estimated $24K sold.
BlackRock first reported a position in ANEB in Q2 2021 and held it in 19 quarters. The position peaked at $60.1K in Q3 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.
- BlackRock reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 23,790 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $24K.
- BlackRock first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- BlackRock's Anebulo Pharmaceuticals position peaked at $60.1K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.